收费全文 | 24719篇 |
免费 | 1174篇 |
国内免费 | 118篇 |
耳鼻咽喉 | 147篇 |
儿科学 | 431篇 |
妇产科学 | 255篇 |
基础医学 | 2827篇 |
口腔科学 | 656篇 |
临床医学 | 1620篇 |
内科学 | 6081篇 |
皮肤病学 | 434篇 |
神经病学 | 1838篇 |
特种医学 | 1152篇 |
外科学 | 4547篇 |
综合类 | 100篇 |
一般理论 | 1篇 |
预防医学 | 833篇 |
眼科学 | 634篇 |
药学 | 1768篇 |
中国医学 | 36篇 |
肿瘤学 | 2651篇 |
2021年 | 337篇 |
2020年 | 238篇 |
2019年 | 328篇 |
2018年 | 419篇 |
2017年 | 320篇 |
2016年 | 408篇 |
2015年 | 422篇 |
2014年 | 523篇 |
2013年 | 727篇 |
2012年 | 1130篇 |
2011年 | 1275篇 |
2010年 | 743篇 |
2009年 | 623篇 |
2008年 | 1163篇 |
2007年 | 1306篇 |
2006年 | 1325篇 |
2005年 | 1290篇 |
2004年 | 1269篇 |
2003年 | 1099篇 |
2002年 | 1134篇 |
2001年 | 934篇 |
2000年 | 946篇 |
1999年 | 813篇 |
1998年 | 322篇 |
1997年 | 241篇 |
1996年 | 249篇 |
1995年 | 176篇 |
1994年 | 189篇 |
1993年 | 166篇 |
1992年 | 545篇 |
1991年 | 504篇 |
1990年 | 491篇 |
1989年 | 487篇 |
1988年 | 423篇 |
1987年 | 409篇 |
1986年 | 412篇 |
1985年 | 397篇 |
1984年 | 243篇 |
1983年 | 191篇 |
1982年 | 96篇 |
1979年 | 184篇 |
1978年 | 115篇 |
1977年 | 105篇 |
1975年 | 90篇 |
1973年 | 95篇 |
1972年 | 91篇 |
1971年 | 85篇 |
1970年 | 110篇 |
1969年 | 93篇 |
1968年 | 87篇 |
Purpose
To evaluate the influence of percutaneous cryoablation for renal cell carcinoma on function of the affected kidney.Materials and Methods
Between June 2016 and September 2017 at our institution, 12 inoperable patients underwent 15 cryoablation sessions for 17 small renal tumors. Of these, 9 patients who underwent 11 sessions of cryoablation were the focus of this study. For those patients, time-dependent changes in postoperative renal function were investigated by a retrospective review of clinical records. Evaluated were the estimated glomerular filtration rate (eGFR) and scintigraphy using 99m technetium-mercaptoacetyltriglycine (99mTc-MAG3) before and 1 week, 1–2 months, and more than 6 months after cryoablation.Results
Mean baseline eGFR was 76.88 ± 29.82 mL/min/1.73 m2 (mean ± standard deviation; range, 23.4–112.5). Mean eGFR 1 week, 1–2 months, and more than 6 months after cryoablation were 74.56 ± 26.68 mL/min/1.73 m2 (21.0–101.1), 69.5 ± 25.28 mL/min/1.73 m2 (24.1–105.6), and 75.08 ± 26.25 mL/min/1.73 m2 (29.0–107.3), respectively. Changes were statistically insignificant (P = .6044, P = .6699, and P = .9038, respectively). Regarding split renal function, the mean baseline contribution of the affected kidney determined by 99mTc-MAG3 was 47.27% ± 6.14 (38.8%–57.0%). Mean contributions of the affected kidney 1 week after, 1–2 months after, and more than 6 months after cryoablation were 44.40% ± 5.37 (38.3%–53.6%), 44.57% ± 6.52 (34.35%–55.0%), and 45.41% ± 7.77 (34.4%–56.5%), respectively. Differences from baseline were significant for the earliest 2 periods (P = .0473 and P = .0334, respectively) but not the later period (P = .2532).Conclusions
Results suggested that total renal function does not worsen after cryoablation; however, function of the affected kidney worsened after cryoablation but later partially recovered. 相似文献2. Rovatirelin orally administered to rats and dogs was rapidly absorbed and bioavailability was estimated to be 7.3 and 41.3%, respectively. The extent of plasma protein binding of rovatirelin in rats, dogs, and humans was low in all species (~15%). The permeability of rovatirelin from blood to brain (permeability-surface area) ranged from 1.04?±?0.14 to 1.29?±?0.28?μL/min/g in rats, and rovatirelin was stable in rat plasma and brain homogenates.
3. The metabolite pattern was qualitatively similar in vitro and in vivo. In animals, rovatirelin aminopentanoic acid (rovatirelin-acid), rovatirelin aminopentanone (rovatirelin-ketone), rovatirelin pyrrolidine (4S)-hydroxy (rovatirelin-OH), (thiazoylalanyl)methylpyrrolidine (TAMP), 3-(4-thiazoyl)-l-alanine (TA), and unknown metabolites were observed. In human hepatocytes, TAMP was mainly formed and no unique human metabolite was observed.
4. The radioactivity from administered [14C]rovatirelin was predominantly excreted in faeces in rats and dogs, and almost all radioactivity was recovered 168?h after administration. Absorption, brain penetration, and stability of rovatirelin in the brain were greater than for taltirelin.
5. Thus, orally administered rovatirelin is a potentially improved treatment for spinocerebellar degeneration compared with taltirelin. 相似文献